Supplementary Fig from Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Autor: Carlos García-Echeverría, William Sellers, Peter Finan, Leon Murphy, Marjo Simonen, Daniela Gabriel, Doriano Fabbro, Kevin Schoemaker, Alain De Pover, Patrick Chène, Saskia Brachmann, Christine Fritsch, Christian Schnell, Pascal Furet, Josef Brueggen, Frédéric Stauffer, Sauveur-Michel Maira

Supplementary Fig from Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d79b465860b280f2050c72dc6f608a8
https://doi.org/10.1158/1535-7163.22484145

Data from Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Autor: Carlos García-Echeverría, William Sellers, Peter Finan, Leon Murphy, Marjo Simonen, Daniela Gabriel, Doriano Fabbro, Kevin Schoemaker, Alain De Pover, Patrick Chène, Saskia Brachmann, Christine Fritsch, Christian Schnell, Pascal Furet, Josef Brueggen, Frédéric Stauffer, Sauveur-Michel Maira

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention. NVP-BEZ235 is an imida

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f474d7f4005db8a169f18e96094e026
https://doi.org/10.1158/1535-7163.c.6531339.v1

Localizing the lipid products of PI3Kγ in neutrophils

Autor: Arnaud Deladeriere, Hervé Guillou, Sabine Suire, Oliver Rausch, G. John Ferguson, Simon Andrews, Simon Walker, Tamara Chessa, Till Bretschneider, Cheng-Jin Du, Laura J. Norton, Anne Segonds-Pichon, Len R. Stephens, Takehiko Sasaki, Peter Finan, Yvonne E. Lindsay, Phillip T. Hawkins, John M. Lucocq

Publikováno v: Advances in Biological Regulation
Advances in Biological Regulation, 2016, 60, pp.36-45. ⟨10.1016/j.jbior.2015.10.005⟩
Advances in Biological Regulation (60), 36-45. (2016)

Class I phosphoinositide 3-kinases (PI3Ks) are important regulators of neutrophil migration in response to a range of chemoattractants. Their primary lipid products PtdIns(3,4,5)P3 and PtdIns(3,4)P2 preferentially accumulate near to the leading edge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ebb156550e35ea5bae9fafd142bb50

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo

Autor: Stephen B. Helliwell, Ayako Honda, Jane Nagel, Xiaohong Mao, Debra Burdick, Julie Bastien, Henry Wang, Suchithra Menon, Hong Lei, Robert Elling, William E. Dowdle, Dirksen E. Bussiere, Mary Ellen Digan, Lawrence G. Hamann, Ivan Cornella-Taracido, Beat Nyfeler, David Schwalb, Dmitri Wiederschain, Savuth Ugwonali, Fred Harbinski, Markus Schirle, Peter Fekkes, Christine D. Wilson, Shanming Liu, Thomas B. Nicholson, Edmund Harrington, Jason R. Thomas, Reginald Valdez, Vic E. Myer, Brendan D. Manning, Erin P. Keaney, John A. Tallarico, Peter Finan, Mark Labow, Gwynn Pardee, Simon D’Aquin, Andrew F. Powers, John Cantwell, Philip Bergman, Qing Fang, Leon Murphy, Zuncai Wang, Mark Knapp, Jenny Kuerth, Ellen Triantafellow, Catherine Luu, Jeffery A. Porter

Publikováno v: Nature Cell Biology. 16:1069-1079

Cells rely on autophagy to clear misfolded proteins and damaged organelles to maintain cellular homeostasis. In this study we use the new autophagy inhibitor PIK-III to screen for autophagy substrates. PIK-III is a selective inhibitor of VPS34 that b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2f917aae57e431c829762b739d3143
https://doi.org/10.1038/ncb3053

Abstract 5014: Profile of ARX001822, a highly potent, selective and orally bioavailable A2a antagonist effective in preventing adenosinergic suppression of T cell activation

Autor: Viral Patel, Jonathan White, Soraya S. Porres, Ben Moulton, Roy Pettipher, Peter Finan, Clive Mccarthy, Steven J. Charlton, Elizabeth M. Rosethorne, Karolina Gherbi

Publikováno v: Cancer Research. 79:5014-5014

Adenosine is elevated in the tumour microenvironment and plays a critical role in suppressing T cell function through high affinity interaction with the A2a receptor. Genetic deficiency of A2a in mice is associated with enhanced cytotoxic responses a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eff7fdde7c97578edb206b575538cffe
https://doi.org/10.1158/1538-7445.am2019-5014